A better buy-in window may exist right now for Replimune Group Inc. (REPL)

Replimune Group Inc. (NASDAQ: REPL) stock jumped 4.58% on Tuesday to $28.78 against a previous-day closing price of $27.52. With 1.0 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.48 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $29.41 whereas the lowest price it dropped to was $27.38. The 52-week range on REPL shows that it touched its highest point at $28.66 and its lowest point at $13.05 during that stretch. It currently has a 1-year price target of $51.50. Beta for the stock currently stands at 1.68.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of REPL was up-trending over the past week, with a rise of 3.60%, but this was up by 8.24% over a month. Three-month performance surged to 50.21% while six-month performance rose 52.44%. The stock gained 38.63% in the past year, while it has gained 5.81% so far this year. A look at the trailing 12-month EPS for REPL yields -2.74 with Next year EPS estimates of -3.09. For the next quarter, that number is -0.75. This implies an EPS growth rate of -29.30% for this year and -3.30% for next year.

Float and Shares Shorts:

At present, 54.77 million REPL shares are outstanding with a float of 45.27 million shares on hand for trading. On Oct 13, 2022, short shares totaled 2.01 million, which was 4.07% higher than short shares on Sep 14, 2022. In addition to Mr. Philip Astley-Sparke FSA as the firm’s CEO & Director, Dr. Robert Coffin Ph.D. serves as its Founder, Pres, Chief R&D Officer and Director.

Institutional Ownership:

Through their ownership of 84.60% of REPL’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 43.45% of REPL, in contrast to 35.10% held by mutual funds. Shares owned by individuals account for 30.56%. As the largest shareholder in REPL with 8.39% of the stake, T. Rowe Price Associates, Inc. holds 4,171,171 shares worth 4,171,171. A second-largest stockholder of REPL, Baker Bros. Advisors LP, holds 3,893,843 shares, controlling over 7.83% of the firm’s shares. Redmile Group LLC is the third largest shareholder in REPL, holding 3,254,412 shares or 6.54% stake. With a 4.61% stake in REPL, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 2,291,822 shares are owned by the mutual fund manager. The T Rowe Price Health Sciences Fund, which owns about 2.72% of REPL stock, is the second-largest Mutual Fund holder. It holds 1,354,276 shares valued at 36.84 million. Vanguard Total Stock Market Index holds 2.69% of the stake in REPL, owning 1,335,904 shares worth 36.34 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for REPL since 10 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With REPL analysts setting a high price target of $70.00 and a low target of $34.00, the average target price over the next 12 months is $51.50. Based on these targets, REPL could surge 143.22% to reach the target high and rise by 18.14% to reach the target low. Reaching the average price target will result in a growth of 78.94% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. REPL will report FY 2023 earnings on 05/18/2023. Analysts have provided yearly estimates in a range of -$2.31 being high and -$3.73 being low. For REPL, this leads to a yearly average estimate of -$2.91. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Replimune Group Inc. surprised analysts by -$0.04 when it reported -$0.79 EPS against a consensus estimate of -$0.75. The surprise factor in the prior quarter was -$0.18. Based on analyst estimates, the high estimate for the next quarter is -$0.63 and the low estimate is -$0.93. The average estimate for the next quarter is thus -$0.75.

Summary of Insider Activity:

Insiders traded REPL stock several times over the past three months with 2 Buys and 1 Sells. In these transactions, 32,500 shares were bought while 15,000 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 12 over the past year. The total number of shares bought during that period was 351,750 while 166,296 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *